Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
Andrée-Anne Pelland, Xavier Deschênes-Simard, Xavier Savard, Philippe Giguère, David Spillane, Frédéric Barabé, Vincent Laroche, Michaël Munger, Geneviève Gallagher, Nicolas Marcoux, Guy Cantin, Maxime Chénard-Poirier, Robert Delage, Marc Lalancette, Olivier Veilleux, Sarit E Assouline, Christopher Lemieux
{"title":"Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.","authors":"Andrée-Anne Pelland, Xavier Deschênes-Simard, Xavier Savard, Philippe Giguère, David Spillane, Frédéric Barabé, Vincent Laroche, Michaël Munger, Geneviève Gallagher, Nicolas Marcoux, Guy Cantin, Maxime Chénard-Poirier, Robert Delage, Marc Lalancette, Olivier Veilleux, Sarit E Assouline, Christopher Lemieux","doi":"10.1080/10428194.2024.2390574","DOIUrl":null,"url":null,"abstract":"<p><p>This study reports characteristics and outcomes of adults who received Azacitidine-Venetoclax (AZA-VEN) compared to other salvage therapies (NO-AZA-VEN) as first salvage therapy for acute myeloid leukemia (AML). The clinical data of 81 patients with a diagnosis of relapsed or refractory AML were analyzed. The ORR was comparable for both groups (55% vs 57%, <i>p</i> = 0.852). Median OS (6.8 vs 11.2 months, <i>p</i> = 0.053) and median RFS (6.9 vs 11.2 months, <i>p</i> = 0.488) showed a trend in favor of the NO-AZA-VEN group. OS was significantly longer with NO-AZA-VEN for ELN 2022 risk category sub-group, patients under 60 years old, primary AML and for patients who underwent allo-hematopoietic stem cell transplant after salvage therapy. There was no statistical difference in complications of treatment such as febrile neutropenia, intensive care unit stay, septic shock and total parenteral nutrition. Those results do not support the preferential use of AZA-VEN over other regimens in R/R acute myeloid leukemia.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2390574","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study reports characteristics and outcomes of adults who received Azacitidine-Venetoclax (AZA-VEN) compared to other salvage therapies (NO-AZA-VEN) as first salvage therapy for acute myeloid leukemia (AML). The clinical data of 81 patients with a diagnosis of relapsed or refractory AML were analyzed. The ORR was comparable for both groups (55% vs 57%, p = 0.852). Median OS (6.8 vs 11.2 months, p = 0.053) and median RFS (6.9 vs 11.2 months, p = 0.488) showed a trend in favor of the NO-AZA-VEN group. OS was significantly longer with NO-AZA-VEN for ELN 2022 risk category sub-group, patients under 60 years old, primary AML and for patients who underwent allo-hematopoietic stem cell transplant after salvage therapy. There was no statistical difference in complications of treatment such as febrile neutropenia, intensive care unit stay, septic shock and total parenteral nutrition. Those results do not support the preferential use of AZA-VEN over other regimens in R/R acute myeloid leukemia.
本研究报告了接受阿扎胞苷- Venetoclax(AZA-VEN)与其他挽救疗法(NO-AZA-VEN)作为急性髓性白血病(AML)首次挽救疗法的成人患者的特征和疗效。研究分析了81名诊断为复发或难治性急性髓细胞白血病患者的临床数据。两组患者的ORR相当(55% vs 57%,P = 0.852)。中位OS(6.8个月 vs 11.2个月,p = 0.053)和中位RFS(6.9个月 vs 11.2个月,p = 0.488)显示出有利于NO-AZA-VEN组的趋势。对于ELN 2022风险类别亚组、60岁以下患者、原发性急性髓细胞白血病患者以及在挽救治疗后接受异体造血干细胞移植的患者,NO-AZA-VEN的OS明显更长。发热性中性粒细胞减少症、重症监护室住院、脓毒性休克和全肠外营养等治疗并发症没有统计学差异。这些结果并不支持在R/R急性髓性白血病中优先使用AZA-VEN而非其他疗法。
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor